Meet our Volunteers of the Month: Elizabeth, Francesca and Verena
Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik. Since March is Women's History Month, we decided to interview these three about their experiences ad volunteers and as women in science.
Elizabeth Macintyre is EHA’s incoming President-elect. She got her MD/PhD is Britain, her PhD in France and post-doc in America. Currently, she is a Professor in diagnostic hematology in Paris Descartes (now Paris University) and Necker-Enfants Malades Hospital since 1992.
She attended her first EHA congress in Brussels in 1992 and regularly since the Florence congress in 2002. She is an active volunteer in EHA committees via the (in order) Scientific Program Committee Advisory Board, Scientific Program Committee, Fellowship and Grants Committee, the EHA Board, HemaSphere and HemaTopics.
Francesca Vinchi is a molecular biotechnologist by training with a PhD in Biomedical Sciences and Human Oncology (Molecular Biotechnology Center-MBC, University of Turin, Italy). She has a PostDoc in Iron Biology (Molecular Medicine Partnership Unit-MMPU, University of Heidelberg & European Molecular Biology Laboratory-EMBL, Germany) and is currently Assistant Professor at the Lindsley Kimball Research Institute, the research branch of the New York Blood Center (NYBC, New York, USA). She joined the NYBC a year ago and started her own Research Program focused on Iron Homeostasis and Hematology as junior principal investigator.
Her connection with EHA started during her PostDoc when she progressively became more involved in the hematology field.
Verena Gaidzik is a physician scientist in the department of Internal Medicine III (Head: Prof. Dr. Hartmut Döhner) at the University Hospital of Ulm. She has board certifications in internal medicine, hematology and oncology as well as palliative medicine. Her research focus is on the genetic characterization and measurable residual disease of acute myeloid leukemia (AML) and its implication on prognosis of AML patients and the respective impact on targeted therapies.
She got to know EHA during the EHA congress in Vienna 2007. From this time, she connected with EHA by attending the annual congress and presenting research work, and has been an EHA member for several years. In 2010, she was awarded the EHA Translational Research Training in Hematology (TRTH). In 2016/2017, she received a Clinical Research Training in Hematology (CRTH) grant.
EHA is a Public Benefit Organization under Dutch law. This means that at least 90% of our efforts are focused on the general good, and profits generated from our activities are solely invested in projects and programs for the benefit of the hematology community. It also means that volunteers are driving our programs and do not receive any salary or financial compensation. These volunteers range from board members to committee members, case writers, external reviewers. Altogether they work for ‘the good cause’ by sharing their knowledge and experience in the broad range of projects and programs EHA is doing. All aimed at lifting hematology to the next level.
Back